Astex Pharmaceuticals Inc has confirmed that it will be halting the development of experimental small-cell lung cancer drug, Amuvatinib. The reason is that the drug failed to achieve a high response rate on an ongoing study.
The main goal of the trial, known as ESCAPE, was to evaluate if the drug achieved a response rate of 10 percent. However Amuvatinib was able to achieve a rate of only 9.5 percent.
AdvertisementThe company said in a statement that no new safety issues were identified during the trial and that it would license the drug to any other companies interested in developing it further.
P New Method Offers Hope of Successful Pregnancy for IVF Couples Despite A Decline South Africa Still Remains The "World Rape Capital" M
You May Also Like